[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640930":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":47,"id":51,"slug":19,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":19,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Michigan State University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Speech Study","EXPERIMENTAL","Single arm study: All speech conditions are administered.",[13],"Behavioral: Behavioral speech strategies + speech amplification",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"BEHAVIORAL","Behavioral speech strategies + speech amplification",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Thea Knowles, PhD","CONTACT","517-353-6401","thea@msu.edu",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","East Lansing","Michigan","48823","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-84.48387,42.73698,{"lat":38,"lon":37},[41,42],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"name":22,"role":43,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"type":43,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Thea Knowles","Assistant Professor",[48],{"name":49,"class":50},"National Institute on Deafness and Other Communication Disorders (NIDCD)","NIH","100640930",false,"NCT07599696","Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements","Speech Amplification Devices for Parkinson and Related Diseases: Talker- and Technology-Driven Enhancements","Inclusion Criteria:\n\n* Dominant speakers of North American English\n* Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP\u002FMSA\u002FPSP)\n* Present with changes in their speech\u002Fvoice\n\nExclusion Criteria:\n\n* History of any other speech, language, or neurological concern other than Parkinson\u002Fparkinsonism.\n* Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and\u002For use of a cochlear implant.","ALL","50 Years",{"count":60,"type":61},100,"ESTIMATED","INTERVENTIONAL",[64],"NA","The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.",[67,68],"Parkinson Disease","Atypical Parkinsonism",[70,71,72,73,74,75,76,77,78,79],"speech","Parkinson's disease","atypical parkinsonism","speech acoustics","speech-language pathology","hypophonia","voice","voice disorders","speech disorders","dysarthria","2026-05-14",{"date":82,"type":83},"2026-05-20","ACTUAL",{"date":85,"type":83},"2024-03-01",{"date":87,"type":61},"2028-05-31",{"name":5,"class":6},1]